<DOC>
	<DOCNO>NCT01809210</DOCNO>
	<brief_summary>This Phase I , open label multicentre study selumetinib administer orally combination first line chemotherapy regimens patient advanced/metastatic NSCLC . The study design allow investigation optimal dose selumetinib combination various standard first line double-platinum chemotherapy regimen . Initial assessment base tolerability selumetinib combination one select regimen consider tolerate also assess preliminary evidence activity . This study dose find optional cohort expansion ; In addition patient assess anti-cancer efficacy combination selumetinib chemotherapy .</brief_summary>
	<brief_title>Assess Safety &amp; Efficacy Selumetinib When Given Combination With Standard First Line Treatment Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>A Phase I , Open Label , Multicentre Study Assess Safety , Tolerability , Pharmacokinetics Preliminary Efficacy Selumetinib ( AZD6244 ; ARRY-142886 ) Combination First Line Chemotherapy Regimens Patients Non-Small Cell Lung Cancer ( NSCLC )</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Provision sign , write dated consent prior study specific procedure Male female , age 18 year old Histological cytological confirmation locally advance metastatic NSCLC ( IIIBIV ) Female patient must breastfeed negative pregnancy test prior start dose must evidence nonchildbearing potential Patients must eligible receive treatment platinum doublet combination selumetinib combine accordance local product information Prior chemotherapy systemic anticancer treatment advance NSCLC . Prior surgery radiotherapy within 6 month palliative radiotherapy within 4 week start study treatment . Female patient breastfeed male female patient reproductive potential employ effective method birth control Another primary malignancy within 5 year start study treatment , except adequately treat basal squamous cell carcinoma skin cancer cervix situ . As judged Investigator , evidence severe uncontrolled systemic disease , active bleeding diatheses , renal transplant , active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>MEK1/2 inhibitor ,</keyword>
	<keyword>Non Small Cell Lung Cancer ,</keyword>
	<keyword>metastatic ,</keyword>
	<keyword>first line treatment Non Small Cell Lung Cancer</keyword>
</DOC>